Inogen Inc. (NASDAQ:INGN) has been assigned an average recommendation of “Buy” from the six analysts that are currently covering the firm. Three equities research analysts have rated the stock with a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $58.00.
A number of equities analysts recently issued reports on the stock. Zacks Investment Research upgraded shares of Inogen from a “hold” rating to a “buy” rating and set a $67.00 price objective for the company in a research report on Tuesday, October 4th. JPMorgan Chase & Co. began coverage on shares of Inogen in a research report on Wednesday, July 13th. They issued an “overweight” rating for the company. Stifel Nicolaus cut shares of Inogen from a “buy” rating to a “hold” rating in a research report on Friday, August 5th. They noted that the move was a valuation call. Finally, Needham & Company LLC restated a “strong-buy” rating and issued a $64.00 price target (up from $58.00) on shares of Inogen in a research report on Sunday, August 7th.
In other news, CEO Raymond Huggenberger sold 20,747 shares of the company’s stock in a transaction on Monday, August 15th. The shares were sold at an average price of $57.48, for a total value of $1,192,537.56. Following the sale, the chief executive officer now directly owns 27,555 shares of the company’s stock, valued at approximately $1,583,861.40. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, EVP Matt Scribner sold 4,551 shares of the company’s stock in a transaction on Wednesday, October 12th. The shares were sold at an average price of $59.45, for a total transaction of $270,556.95. Following the completion of the sale, the executive vice president now directly owns 6,884 shares in the company, valued at $409,253.80. The disclosure for this sale can be found here. 5.18% of the stock is currently owned by insiders.
Several large investors have recently bought and sold shares of INGN. TIAA CREF Investment Management LLC raised its stake in Inogen by 0.9% in the first quarter. TIAA CREF Investment Management LLC now owns 100,661 shares of the medical technology company’s stock worth $4,528,000 after buying an additional 940 shares in the last quarter. Teachers Retirement System of The State of Kentucky raised its stake in Inogen by 66.7% in the second quarter. Teachers Retirement System of The State of Kentucky now owns 6,000 shares of the medical technology company’s stock worth $301,000 after buying an additional 2,400 shares in the last quarter. Bayesian Capital Management LP purchased a new stake in Inogen during the first quarter worth approximately $238,000. Nationwide Fund Advisors raised its stake in Inogen by 62.3% in the second quarter. Nationwide Fund Advisors now owns 77,139 shares of the medical technology company’s stock worth $3,865,000 after buying an additional 29,597 shares in the last quarter. Finally, Bogle Investment Management L P DE purchased a new stake in Inogen during the first quarter worth approximately $861,000.
Shares of Inogen (NASDAQ:INGN) traded up 2.66% during midday trading on Tuesday, hitting $57.87. 68,791 shares of the company were exchanged. Inogen has a one year low of $28.81 and a one year high of $61.87. The firm has a market capitalization of $1.16 billion, a price-to-earnings ratio of 85.10 and a beta of 0.88. The firm’s 50 day moving average price is $59.13 and its 200 day moving average price is $52.30.
Inogen (NASDAQ:INGN) last released its quarterly earnings data on Thursday, August 4th. The medical technology company reported $0.25 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.20 by $0.05. The business earned $54.57 million during the quarter, compared to analysts’ expectations of $52.44 million. Inogen had a net margin of 7.86% and a return on equity of 9.50%. The firm’s quarterly revenue was up 23.9% compared to the same quarter last year. During the same period in the prior year, the company earned $0.17 EPS. Analysts forecast that Inogen will post $0.63 EPS for the current fiscal year.
Inogen, Inc is a medical technology company. The Company is engaged in developing, manufacturing and marketing portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The Company’s Inogen One systems concentrate the air around the patient to offer a single source of supplemental oxygen anytime, anywhere with a portable device weighing approximately 4.8 or seven pounds.
Receive News & Ratings for Inogen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.